Our data suggest the possibility that inhibition of SPN function might sensitize cancers to treatment with CD3 bsAb (as well as to other immunotherapies, since SPN significantly affects the ability of tumor cells to cluster with T cells even in the absence of CD3 bsAb). Here, SPN is linked to cancer.